Equity · Healthcare
VVOS
NASDAQVivos Therapeutics, Inc.
$0.4156
+2.29% vs prior close
Finazon · prior-day close, indicative (IEX-derived, not the official close) · Jul 17, 2026
Price · Chart
$0.48
$0.40
8 Jul
17 Jul
The line runs $0.4798 on 8 July through $0.4156 on 17 July, on a scale from $0.40 to $0.48. Days the market did not trade hold the previous close, flat.
Market cap
$8.4M
Avg volume
116.4K
as of Jul 17, 2026
Filings 4 sets
VVOS reported financials
SEC EDGARVVOS reported revenue of $17.4M for the fiscal year ended 31 Dec 2025. Net income over the same period was −$21.2M.
Figure
Reported
Period
Revenue
$17.4M
31 Dec 2025
fiscal year
Net income
−$21.2M
31 Dec 2025
fiscal year
Diluted EPS
−$2.07
31 Dec 2025
fiscal year
Total assets
$24.1M
30 Jun 2026
at period end
Total equity
−$3.8M
30 Jun 2026
at period end
VVOS earnings
Date
Period
EPS
Revenue
30 Jun 2026
Q2 2026
−$0.31
$5M
31 Mar 2026
Q1 2026
−$0.52
$5M
31 Dec 2025
FY 2025
−$2.07
$17M
30 Sep 2025
Q3 2025
−$0.49
$7M
30 Jun 2025
Q2 2025
−$0.55
$4M
31 Mar 2025
Q1 2025
−$0.45
$3M
31 Dec 2024
FY 2024
−$2.22
$15M
30 Sep 2024
Q3 2024
−$0.40
$4M
no date announced in SEC filings yet
Reported figures & scheduled dates · SEC EDGAR filings
VVOS institutional holders
SEC EDGAR0 of the 45 institutional funds we track reported a VVOS position for the quarter ended 31 Dec 2025; the latest of those filings landed 12 Feb 2026.
Fund
Action
Shares
Value
VVOS fails-to-deliver
SECOn 14 Sep 2026, 8,229 shares of VVOS failed to deliver (about $1K).
Settlement date
Shares failed
Notional
% of shares out
14 Sep 2026
8,229
$1K
0.041%
10 Sep 2026
354
$60
0.002%
09 Sep 2026
3,329
$599
0.017%
08 Sep 2026
2,245
$427
0.011%
03 Sep 2026
138,153
$23K
0.687%
02 Sep 2026
410,370
$70K
2.040%
01 Sep 2026
11,976,326
$2.4M
59.530%
31 Aug 2026
75,983
$17K
0.378%
28 Aug 2026
4,836
$1K
0.024%
27 Aug 2026
269,920
$67K
1.342%
26 Aug 2026
11,879
$3K
0.059%
25 Aug 2026
45
$13
<0.001%
24 Aug 2026
2,217
$665
0.011%
Sources
- Finazonprior-day close, indicative (IEX-derived, not the official close)
- TradingViewthe price chart widget, drawn by TradingView from their own data
- SEC EDGARSEC EDGAR XBRL company facts · latest period ended 30 Jun 2026
- SEC EDGARSEC EDGAR 13F filings
- SECSEC fails-to-deliver (CNS) data
- SEC EDGARValuation computed from SEC EDGAR filings